Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Summary

This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to treat brain tumors in a pediatric population. Researchers want to see if treatment with PEG-Intron will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic pathway gliomas. The purposes of this study are: * To learn more about the response to pegylated interferon * To learn more about the side effects of pegylated interferon * To learn more about MRI images in patients with Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas. * To learn more about quality of life in patients treated with pegylated interferon

Timeline

Start

2014-11

Primary completion

2020-11-11

Completion

2020-11-11

Drugs

Indications